AI Article Synopsis
- The study aimed to assess the short-term efficacy and safety of fesoterodine fumarate in patients with Parkinson's disease who experience overactive bladder symptoms.
- It was a randomized, double-blind, placebo-controlled trial involving 63 patients over two phases, with the primary focus on the change in micturition episodes over a 24-hour period.
- Results showed a significant improvement in micturition, urgency, and nocturia episodes for those taking fesoterodine, while cognitive functions remained stable throughout the treatment.
Article Abstract
Aims: To evaluate short-term efficacy and safety of fesoterodine fumarate in Parkinson's disease (PD) patients with overactive bladder (OAB) symptoms.
Methods: This is a randomized, double-blind, placebo-controlled study. It also has an open-label extension phase. From May 2016 to May 2018, 63 patients were randomized to receive fesoterodine 4 mg or placebo for 4 weeks. At the end of 4 weeks of randomization phase, patients were received fesoterodine fumarate 4 mg daily for another 4 weeks at the open-label extension phase. The change in the mean number of micturition episodes per 24 h period was the primary outcome measure of the study.
Results: The number of micturition episodes per 24 h period significantly improved with the use of fesoterodine fumarate in the double-blind phase (p < 0.001). Also the mean number of nocturia and urgency episodes decreased in the fesoterodine group. In the open-label phase, the mean number of micturition, urgency and urgency urinary incontinence episodes were improved significantly. The number of nocturia episodes did not change in the open-label phase. Cognitive functions were stable after 4 weeks of fesoterodine 4 mg treatment.
Conclusions: OAB symptoms were significantly improved in older adults with PD under fesoterodine fumarate treatment, and this advantage continued in the open-label portion in the short term. In this randomized controlled study, the cognitive functions of the participants were not affected by fesoterodine 4 mg treatment compared with placebo.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00345-019-02981-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study.
BMJ Med
November 2024
Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.
Article Synopsis
- The study aimed to assess the risk of developing dementia associated with different anticholinergic drugs prescribed for overactive bladder among older adults in England.
- Utilizing data from the Clinical Practice Research Datalink, researchers conducted a nested case-control study involving over 170,000 patients diagnosed with dementia, alongside matched controls without dementia.
- Results indicated a slightly elevated risk of dementia (odds ratio of 1.18) linked to anticholinergic drug use, with a higher risk observed in men compared to women.
Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database.
Heliyon
October 2024
Department of Oral and Maxillofacial Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223300, Jiangsu Province, China.
Article Synopsis
- The study investigates the link between various medications and drug-induced dry mouth, which impacts patients' quality of life.
- Data was collected from the FDA's Adverse Event Reporting System from 2004 to 2024, analyzing 75,899 reports of dry mouth.
- Findings indicated tiotropium bromide monohydrate was most commonly reported for causing dry mouth, while darifenacin had the highest risk; many implicated drugs lacked proper labeling for this side effect.
An Investigational Study on the Role of , and s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers.
Pharmaceuticals (Basel)
September 2024
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain.
Fesoterodine is one of the most widely used antimuscarinic drugs to treat an overactive bladder. Fesoterodine is extensively hydrolyzed by esterases to 5-hydroxymethyl tolterodine (5-HMT), the major active metabolite. CYP2D6 and CYP3A4 mainly metabolize 5-HMT and are, therefore, the primary pharmacogenetic candidate biomarkers.
View Article and Find Full Text PDFAn update on the cognitive safety of antimuscarinics in the treatment of overactive bladder.
Expert Opin Drug Saf
October 2024
Department of Urology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
Article Synopsis
- Antimuscarinics are the primary medications for treating overactive bladder (OAB), especially in older adults, but their effects on cognitive function have raised concerns for over ten years.
- A comprehensive review of studies was conducted to assess the cognitive safety of various antimuscarinic drugs, highlighting both recent and earlier findings.
- While some medications like oxybutynin may impair cognition, others like darifenacin and fesoterodine show promise but need more research, suggesting careful monitoring and further studies are necessary for safer treatment options in patients, especially those with cognitive issues.
The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review.
Indian J Urol
April 2024
Department of Surgery, Western University, London, Ontario, Canada.
This narrative review discusses the relationship between anticholinergic medications and cognitive change specifically in patients with neurogenic lower urinary tract dysfunction (NLUTD). NLUTD is prevalent in various conditions, including spinal cord injury (SCI), spina bifida (SB), multiple sclerosis (MS), Parkinson's, stroke, and dementia and often requires anticholinergic overactive bladder (OAB) medications. In the general population, and among those with OAB, several studies have found a significant association between this class of medications and cognitive side effects, mostly when used for > 90 days.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!